Dr. Kohei Shimada serves as chief scientific officer at GEXVal Inc., a spin-off from a major pharmaceutical company. Following a three-decade career at Daiichi Sankyo that included studies across multiple therapeutic areas including inflammatory diseases, Dr. Shimada conducted research as a visiting scientist at City of Hope National Medical Center. His expertise spans drug discovery to management of open innovation. At GEXVal, Dr. Shimada focuses on generating new value for drug candidates through extensive collaborations with patient advocacy organizations and academic researchers. Under his leadership, GEXVal is pioneering a development model that combines expertise with partnerships to accelerate the delivery of life-changing therapeutic options to patients and family. GEXVal applies innovative pharmacoinformatics technology to early-stage drug development for rare neurological disorders and developmental disorders, addressing critical unmet needs.